{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'APPENDIX 2 - SYNVISC-ONE INSTRUCTIONS FOR USE', 'Version #: 4.0', 'Page 57 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'SYNVISC ONE', 'Rx Only', 'Arthritis', 'HYLAN G-F 20', 'Arthropathy', 'Package contents provided sterile.', 'Gait disturbance', 'Genzyme Biosurgery, a division of Genzyme Corporation', '1125 Pleasant View Terrace', 'A complete list of the frequency and rate of adverse events identified in the clinical study', 'Ridgefield, New Jersey 07657', 'are provided in the Safety section (Table 2).', 'Telephone: 1-888-3-SYNVISC (1-888-379-6847)', 'Post-marketing Experience', 'www.synvisc.com', 'SYNVISC (3-injection regimen) post-marketing experience has identified the following', 'Information for Prescribers', 'systemic events to occur rarely with administration: rash, hives, itching, fever, nausea,', 'Caution: Federal law restricts this device to sale by or on the order of a physician (or', 'headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise,', 'property licensed practitioner).', 'respiratory difficulties, flushing and facial swelling. There have been rare reports of', 'DESCRIPTION', 'thrombocytopenia coincident with SYNVISC (3-injection regimen) injection.', 'Synvisc-One (hylan G-F 20) is an elastoviscous high molecular weight fluid containing', 'Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, ana-', 'hylan A and hylan B polymers produced from chicken comba Hylans are derivatives of', 'phylactic shock and angioedema have been reported.', 'hyaluronan (sodium hyaluronate). Hylan G-F 20 is unique in that the hyaluronan is', 'PIVOTAL CLINICAL TRIAL', 'chemically crosslinked. Hyaluronan is a long-chain polymer containing repeating', 'disaccharide units of Na-glucuronate-N-acetylglucosamine.', 'Study Design', 'INDICATIONS FOR USE', 'To determine the safety and effectiveness of a single injection regimen of Synvisc-One in', 'Synvisc-One is indicated for the treatment of pain in ostecarthritis (OA) of the knee in', 'the reduction of the pain score in osteoarthritis of the knee, a prospective, randomized,', 'patients who have failed to respond adequately to conservative nonpharmacologic therapy', 'double-blind, 2-arm (parallel group) clinical trial in 21 centers in six European countries', 'and simple analgesics, e.g., acetaminophen.', 'was conducted. A total of 253 patients were randomly assigned to study treatment; 123', 'CONTRAINDICATIONS', 'received 6 mL of Synvisc-One and 130 received 6 mL of Phosphate-Buffered Saline.', 'Do not administer to patients with known hypersensitivity (allergy) to hyaluronan', 'Neither the patients nor the clinical observers knew the patients treatment allocations. The', '(sodium hyaluronate) preparations', 'outcome measures collected included the Western Ontario and McMaster Universities', 'Do not inject Synvisc-One in the knees of patients having knee joint infections or skin', 'Osteoarthrifis Index (WOMAC; Likert 3.1. version); patient global assessment (PTGA);', 'diseases or infections in the area of the injection site.', 'clinical observer global assessment (COGA); and use of rescue analgesic (see Treatment', 'WARNINGS', 'and Evaluation Schedule). The intent-to-treat (ITT) population (al patients randomized)', 'Do not concomitantly use disinfectants containing quatemary ammonium saits for skin', 'was used for the primary analysis. The primary efficacy analysis was a comparison over', 'preparation because hyaluronan can precipitate in their presence.', '26 weeks between the two treatment groups of change from baseline in the WOMAC A', 'Do not inject Synvisc-One extra-articularly or into the synovial fissues and capsule.', '(Pain) Subscale (see Patient Population and Demographics), performed by analysis of', 'Intravascular injections of Synvisc-One may cause systemic adverse events.', 'covariance (ANCOVA).', 'PRECAUTIONS', 'Patient Population and Demographics', 'General', 'Study patients had primary osteoarthritis of the knee per American College of Rheuma-', 'The safety and efficacy of Synvisc-One in locations other than the knee and for', 'tology criteria and were at least 40 years old. The diagnosis was confirmed via recent', 'conditions other than osteoarthrifis have not been established.', 'radiograph showing at least one osteophyte in the target knee. Study patients had', 'The safety and effectiveness of the use of Synvisc-One concomitantly with other', 'continued target knee pain despite use of conservative treatment and analgesics/non-', 'intra-articular injectables have not been established.', 'steroidal anti-inflammatory drugs (NSAIDs). Patients with severe disease (Grade IV) per', 'Use caution when injecting Synvisc-One into patients who are allergic to avian', 'Kellgren-Lawrence criteria) or who had prior arthroplasty in the target knee, were excluded', 'proteins, feathers or egg products.', 'At the beginning of the study, subjects had moderate or severe target knee pain when', 'The safety and efficacy of Synvisc-One in severely inflamed knee joints have not been', 'walking on a flat surface (on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate,', 'established.', '3 = severe 4 = extreme), and an average score of 1.5 to 3.5 on the five questions of the', 'Strict aseptic administration technique must be followed', 'WOMAC A (Pain) Subscale. The WOMAC A Subscale asks study subjects to rate their', 'STERILE CONTENTS. The syringe is intended for single use. The contents of the', 'degree of pain when:', 'syringe must be used immediately after its packaging is opened. Discard any unused', '1. Walking on a flat surface', 'Synvisc-One', '2. Going up and down stairs', 'Do Synvisc-One if package is opened or damaged. Store in original packaging', '3. Resting during the night', '(protected from light) at room temperature below 86\u00b0F (30\u00b0C). DO NOT FREEZE', 'Remove any synovial fluid or effusion before injecting Synvisc-One.', '4. Sitting or lying', 'Synvisc-One should be used with caution when there is evidence of lymphafic or', '5. Standing upright', 'venous stasis in the leg to be injected.', 'Table 1 summarizes the demographics and baseline characteristica. There were no', 'Information for Patients', 'clinically meaningful differences between treatment groups in any baseline parameter.', 'Provide patients with a copy of the Patient Labeling prior to use.', 'Treatment and Evaluation Schedule', 'Mild to moderate pain, swelling and/or effusion of the injected knee have been', 'Initial Treatment Phase', 'reported in clinical trials that were related to intra-articular injection of Synvisc-One.', 'Patients were followed for 26 weeks. Study visits were scheduled for screening, baseline,', 'These events were typically transient and usually resolved on their own or with', 'and weeks 1, 4, 8, 12, 18 and 26. Injections were performed aseptically at the baseline', 'conservative treatment', 'visit after arthrocentesis to withdraw any effusion or synovial fluid present Patients were', 'As with any invasive joint procedure, it is recommended that the patient avoid', 'not permitted to take long-acting NSAIDs (including cyclo-ouygenase Il inhibitors), opioid', 'strenuous activities (for example, high-impact sports such as soccer, tennis or', 'analgesics or corticosteroids (by any route) during the study, but were permitted to take', 'jogging) or prolonged weight-bearing activities for approximately 48 hours following', 'up to 4 g per day of acetaminophen as needed for \"rescue\" of inj\u00e9cted knee pain.', 'the intra-articular injection. The patient should consult his or her physician regarding', '\"Rescue\" medication was not permitted within 48 hours of any study visit Injected knee', 'the appropriate time to resume such activities.', 'assessment, patient and clinician global assessments (PTGA & COGA), WOMAC and', 'Use in Specific Populations', 'safety evaluations were performed at each study visit', 'Pregnancy: The safety and effectiveness of Synvisc-One have not been established', 'Repeat Treatment Phase', 'in pregnant women.', 'If patients in either blinded treatment group had at least mild pain in the injected knee at', 'Nursing mothers: It is not known if Synvisc-One is excreted in human milk. The', 'the week 26 visit (and did not experience any significant clinical concerns after the first', 'safety and effectiveness of Synvisc-One have not been established in lactafing', 'treatment administration), they were offered an injection of (open-label) Synvisc-One.', 'women.', 'Those who chose to receive the second injection were followed for 4 weeks for safety only.', 'Pediatrics: The safety and effectiveness of Synvisc-One have not been established', 'Adverse Event Summary', 'in pediatric patients Pediatric patients are defined as patients < 21 years of age.', 'The frequency and type of adverse events (AEs) were similar between the group of', 'POTENTIAL ADVERSE EFFECTS OF THE DEVICE ON HEALTH', 'patients that received Synvisc-One and the group that received saline control.', 'Reported Device-Related Adverse Events', 'Initial Treatment Phase: The overal proportions of patients with Treatment-Emergent', 'The most commonly reported adverse events associated with Synvisc-One are the', 'AEs regardless of device relatedness (Synvisc-One n=70, 56.9%; Saline Controlt n=79,', 'following:', '60.8%) and with injected knee AEs regardless of device relatedness (Synvisc-Onel n=44,', 'Arthralgia', '35.8% Saline Control: n=44, 33.8 were comparable between the two treatment groups', 'Arthritis', '(See Table 2). Table 3 lists the incidences of AEs in the injected knee that were assessed', 'Arthropathy', 'by the investigator to be device-related, defined as related to either the study injection or', 'Injection site pain', 'the study treatment.', 'Joint effusion', 'Device-related AEs involving the injected knee were mild or moderate in nature and were', 'A complete list of the frequency and rate of adverse events identified in the clinical study', 'treated symptomatically. There were no serious AEs in the injected knee in either the', 'are provided in the Safety section (Table 3).', 'Pot\u00e9ntial Adverse Events', 'Synvisc-One or the saline control group.', 'Repeat Treatment Phase: The repeat treatment phase evaluated the safety profile of the', 'The following adverse events are among those that may occur in association with', 'initial phase of patients receiving a second injection of Synvisc-One. One hundred and', 'intra-articular injections, including Synvisc-One', 'sixty patients were treated during this phase of the study, of which 77 patients received', 'Arthralgia', 'a second injection of Synvisc-One. Of these 77 patients, 4 (5.2%) experienced five device', 'Joint stiffness', 'related AEs in the injected knee. All such events were mild to moderate and were treated', 'Joint effusion', 'symptomatically. These events were arthralgia (n=2), arthritis (n=1), injection hematoma', 'Joint swelling', '(n=1) and injection site pain (n=1). Patients who developed injected knee AEs during the', 'Joint warmth', 'initial phase of the study, and who subsequently received repeat treatment, did not', 'Injection site pain', 'experience injected knee AEs upon repeat exposure to Synvisc-One.', '1', 'version #: 4.0', 'Page 58 of', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}